Lo et al. [89] developed two lipid-polymeric NPs (LPNs)—Afa/LPN-FD7 and Afa/LPN-CCD—functionalized with tight junction-modulating peptides (FD7 and CCD) to enhance the delivery of Afa across the BBB for the treatment of EGFR-positive NSCLC BM and reduce its adverse effects. This evidence concerns the gene EGFR and non-small cell lung carcinoma.